Loading...
•
Sep 30, 2021
DBV Technologies Q3 2021 Earnings Report
Reported third quarter 2021 financial results and recent regulatory developments.
Key Takeaways
DBV Technologies reported financial results for the third quarter of 2021. Cash and cash equivalents were $98.2 million as of September 30, 2021. Net loss was $(24.0) million, or $(0.44) per share.
Cash and cash equivalents totaled $98.2 million as of September 30, 2021.
The FDA requested a stepwise approach to DBV’s modified Viaskin Peanut (mVP) development program and would like to review the data from DBV’s protein uptake release study prior to providing additional comments on the STAMP protocol design.
The EMA review of the Viaskin Peanut Marketing Authorization Application is progressing.
DBV expects that its current cash and cash equivalents will support its operations into the third quarter of 2022.